Targeting Immunotherapy to the Tumor Microenvironment.
Targeting drugs to the tumor microenvironment has long been appreciated as a means of increasing local concentrations and decreasing systemic toxicities. How drug targeting might apply to immune-based therapies is less clear. In this review, we explain the immunology of cancer, with a focus on the principles of in situ vaccination. Certain types of therapies are more amenable to local versus systemic delivery; these include cytokines, adjuvants, radiation, and agents targeting tumor-resident cell populations. Several approaches for targeting the tumor microenvironment are under development. Nanoparticles, peptide or antibody-based delivery, and exploitation of cellular influx are all promising ways to delivery immune modulating compounds to tumors. J. Cell. Biochem. 118: 3049-3054, 2017. © 2017 Wiley Periodicals, Inc.
Massachusetts General Hospital, Boston, Massachusetts, 02114.
Michael
M
Dougan
Dana-Farber Cancer Institute, Boston, Massachusetts, 02215.|Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, 02115.
Stephanie K
0000-0002-2263-363X
SK
Dougan
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D059016:Tumor Microenvironment / Q000187:drug effects*
D000970:Antineoplastic Agents
CANCER IMMUNOLOGY; DRUG TARGETING; IMMUNOTHERAPY; TUMOR MICROENVIRONMENT